Fourthly, the efficacy and safety of SGLT2 inhibitors in people with established kidney failure requiring dialysis or kidney transplant remains to be evaluated (eg, NCT05374291), and data are insufficient to assess the effects on kidney and cardiovascular clinical outcomes for patients with other kidney diagnoses excluded from the chronic kidney disease trials (eg, polycystic kidney disease) and for patients with type 1 diabetes (appendix p 8).44, 60 Finally, our absolute effect estimates are specific to the recruited trial populations. This evidence concerns the gene SLC5A2 and polycystic kidney disease.